chr7-44151075-G-C
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PP1_ModeratePM5_SupportingPP2PP3PP4PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The c.364C>G variant in the glucokinase gene, GCK, causes an amino acid change of leucine to valine at codon 122 (p.(Leu122Val)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.948, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 3 unrelated individuals with hyperglycemia; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (PMIDs: 11508276, 32468610, internal lab contributors). Two of these individuals and one relative had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; PMID:32468610, internal lab contributors). This variant segregated with hyperglycemia, with 3 informative meioses in 2 families (PP1; PMIDs: 32468610). Another missense variant, c.364C>T, p.Leu122Phe, has been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting). Taken together, this evidence supports the classification of c.364C>G as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Moderate, PM5_Supporting, PM2_Supporting, PP2, PP3, PP4. LINK:https://erepo.genome.network/evrepo/ui/classification/CA367402231/MONDO:0015967/086
Frequency
Consequence
ENST00000403799.8 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GCK | NM_000162.5 | c.364C>G | p.Leu122Val | missense_variant, splice_region_variant | 4/10 | ENST00000403799.8 | NP_000153.1 | |
GCK | NM_033507.3 | c.367C>G | p.Leu123Val | missense_variant, splice_region_variant | 4/10 | NP_277042.1 | ||
GCK | NM_033508.3 | c.361C>G | p.Leu121Val | missense_variant, splice_region_variant | 5/11 | NP_277043.1 | ||
GCK | NM_001354800.1 | c.364C>G | p.Leu122Val | missense_variant, splice_region_variant | 4/11 | NP_001341729.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GCK | ENST00000403799.8 | c.364C>G | p.Leu122Val | missense_variant, splice_region_variant | 4/10 | 1 | NM_000162.5 | ENSP00000384247 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 22, 2022 | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 122 of the GCK protein (p.Leu122Val). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of autosomal dominant maturity onset diabetes of the young (PMID: 11508276, 32468610). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 585919). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant disrupts the p.Leu122 amino acid residue in GCK. Other variant(s) that disrupt this residue have been observed in individuals with GCK-related conditions (PMID: 15928245, 31905448), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Aug 17, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Apr 06, 2020 | - - |
Monogenic diabetes Pathogenic:1
Likely pathogenic, reviewed by expert panel | curation | ClinGen Monogenic Diabetes Variant Curation Expert Panel | Mar 11, 2024 | The c.364C>G variant in the glucokinase gene, GCK, causes an amino acid change of leucine to valine at codon 122 (p.(Leu122Val)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.948, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 3 unrelated individuals with hyperglycemia; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (PMIDs: 11508276, 32468610, internal lab contributors). Two of these individuals and one relative had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (PP4; PMID: 32468610, internal lab contributors). This variant segregated with hyperglycemia, with 3 informative meioses in 2 families (PP1; PMIDs: 32468610). Another missense variant, c.364C>T, p.Leu122Phe, has been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting). Taken together, this evidence supports the classification of c.364C>G as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1_Moderate, PM5_Supporting, PM2_Supporting, PP2, PP3, PP4. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at